Directori

MARTA SITGES ARRIAGA

Hematología

Firma

MARTA SITGES-ARRIAGA

Posición

Investigadors/es Col·laboradors/es

Investigadores/as Colaboradores/as

Publicacions

Hematología

Gonzalez-Gil C, Morgades M, Lopes T, Fuster-Tormo F, Montesinos P, Barba P, Diaz-Beya M, Hermosin L, Maluquer C, Gonzalez-Campos J, Bernal T, Arriaga MS, Zamora L, Pratcorona M, Martino R, Larrayoz MJ, Artola T, Torrent A, Vall-Llovera F, Tormo M, Gil C, Novo A, Martinez-Sanchez P, Ribera J, Queipo MP, Gonzalez-Martinez T, Cabrero M, Cladera A, Cervera J, Orfao A, Ribera JM, Genesca E

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Haematologica, 2025, 110, 206-211 dx.doi.org/10.3324/haematol.2024.285416

Hematología

Bento L, Gutiérrez A, Martínez C, Ortí Verdet MC, Sorribes M, Caballero AC, Peña M, Pérez A, Jiménez-Ubieto A, Medina L, Bastos-Oreiro M, Caldas-González PF, Navarro B, Salcedo I, Abrisqueta P, Español I, Cornago J, Martín-Moro F, García L, Gómez P, Varela MR, Puente M, Zanabili J, Zudaire T, Zeberio I, Del Campo R, González L, González P, Blázquez C, Rovira J, Sitges M, Franch-Sarto M, Cabero A, Mussetti A, Montoro J, Sampol A, Sureda A, Caballero D, Martín García-Sancho A

Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study.

Blood Advances, 2025, 9, 3281-3292 dx.doi.org/10.1182/bloodadvances.2024015415

Hematología

Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

Haematologica, 2024, 109, 543-552 dx.doi.org/10.3324/haematol.2023.283342

Hematología

Díaz-Santa J, Rodríguez-Romanos R, Coll R, Osca G, Pratcorona M, González-Bártulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Díez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D

5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics

EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109, 755-764 dx.doi.org/10.1111/ejh.13862

Hematología

Sitges M, Boluda B, Garrido A, Morgades M, Granada I, Barragan E, Arnan M, Serrano J, Tormo M, Miguel Bergua J, Colorado M, Salamero O, Esteve J, Benavente C, Pérez-Encinas M, Coll R, Martí-Tutusaus JM, Brunet S, Sierra J, Ángel Sanz M, Montesinos P, Ribera JM, Vives S

Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols

EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105, 138-147 dx.doi.org/10.1111/ejh.13417

Formulari de contacte

Patronato

Centro de

Directori

MARTA SITGES ARRIAGA

Publicacions

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials.

Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study.

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics

Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols

Formulari de contacte

Conoce el IDIBGI!